Cagrisema 99% Purity Weight Loss Peptides Cagrisema (2.5mg+2.5mg) Overweight or Obesity Adults

Basic Properties & Mechanism of Action

CagriSema is a fixed-dose combination therapy consisting of an amylin analog (cagrilintide) and a GLP-1 receptor agonist (semaglutide), administered via once-weekly subcutaneous injection. Its dual-pathway design integrates complementary metabolic regulation mechanisms:

• Cagrilintide: Activates amylin and calcitonin receptors (AMYR/CTR), suppressing appetite and delaying gastric emptying.

• Semaglutide: Enhances insulin secretion, inhibits glucagon release, and synergistically modulates feeding behavior.
  The components demonstrate cooperative action for dual control of energy intake and glucose metabolism .

Clinical Research Findings

1. Weight Management

• Non-diabetic population (REDEFINE-1, n=3,417):
  20.4% mean weight reduction after 68 weeks; 53.6% of participants achieved ≥20% weight loss. Fully adherent subgroup reached 22.7% reduction.

• Type 2 diabetes population (REDEFINE-2, n=1,206):
  13.7% mean weight loss; 73.5% achieved glycemic target (HbA1c ≤6.5%).

2. Metabolic Improvements

• Glycemic control: HbA1c reduction of 2.18% from baseline, significantly exceeding monotherapy outcomes.

• Additional benefits: Concurrent improvements in blood pressure, lipid profiles, and insulin sensitivity.

Efficacy Comparison (68-week data)

1. 1. •  Safety & Tolerability

        • Primary adverse events: Mild-to-moderate gastrointestinal incidents (nausea, vomiting, diarrhea; ~72.5% incidence), predominantly during dose escalation and typically transient.

        • No new safety signals: No clinically significant cardiovascular or neuropsychiatric adverse events observed in trials.

        • Dosing flexibility: Dynamic dose adjustment permitted, with lowest discontinuation rate in class (<5%).

        ---

        Development Status & Research Directions

        1. Indication focus:

           • Core targets: Obesity (BMI≥30) and type 2 diabetes with obesity.

           • Long-term cardiometabolic outcome studies (REDEFINE 3/4) expected 2025.

        2. Competitive assessment:

           • Active head-to-head Phase III trial vs. tirzepatide (n=800; results 2025).

        3. Formulation optimization:

           • Exploring oral (e.g., Amycretin) and monthly injectable formulations to improve adherence.